Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy

Journal of B.U.ON.

Volumn 16, Issue 4, 2011, Pages 708-714

  Milovic Kovacevic, Marijana ^a   Srdic Rajic, T ^a   Radulovic, S ^a   Bjelogrlic, S ^a   Gavrilovic, D ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

ERCC1; NER; Ovarian cancer; Platinum based chemotherapy

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR BIOPSY; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; INFANT; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855459883     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. Int J Gynaecol 2003; 83: 135-166. (Pubitemid 39658498)
2. Whittemore AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol 1994; 55: 15-19.
3. Itamochi H, Rigawa J, Akeshima R et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 2002; 62: 349-353. (Pubitemid 34914104)
4. Dabholkar M, Vionnet JA, Bostick-Bruton F et al. mRNA levels of XPAC and ERCC1 in ovarian tumor tissue correlates with response to platinum containing chemotherapy. J Clin Investig 1994; 94: 703-708. (Pubitemid 24251002)
5. Metzger R, Leichman CG, Danenberg RD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316. (Pubitemid 28041614)
6. Shirota Y, Stoehlmach, J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-4304. (Pubitemid 33096777)
7. Yamada M, Tomida A, Yun J et al. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother Pharmacol 1999; 44: 59-64. (Pubitemid 29246326)
8. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
9. Xu Z, Chen ZP, Malapetsa A et al. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 2002; 13: 511-519. (Pubitemid 34621055)
10. Olaussen RA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991. (Pubitemid 44343542)
11. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-2589. (Pubitemid 30331967)
12. Weberpals JI, Clark-Knowles RV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 2008; 26: 3259-3267.
13. Weberpals J, Garbuio K, O'Brien A et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 2009; 124: 806-815.
14. Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-887. (Pubitemid 13014028)
15. Gilani MM, Karimi Zarchi M, Ghaemmaghami F et al. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol Oncol 2007; 105: 780-783. (Pubitemid 46734210)
16. Li Q, Ding L, Yu JJ et al. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Int J Oncol 1998; 13: 987-992. (Pubitemid 28506069)
17. Li Q, Gardner K, Zhang L et al. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70B human ovarian cancer cells. J Biol Chem 1998; 273: 23419-23425. (Pubitemid 28417531)
18. Selvakumaran M, Pisarcik DA, Bao R et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63: 1311-1316. (Pubitemid 36348710)
19. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25: 2747-2754. (Pubitemid 47123183)